Advertisement

Topics

Search Results for "CT P6 Celltrion"

22:12 EDT 1st July 2016 | BioPortfolio

Matching Channels

None

Matching News

INTERVIEW: The Biosimilar Brain - Celltrion’s Dr. Stanley Hong

South Korean firm Celltrion Healthcare is a pioneer in the biosimilar space, having launched the world's first monoclonal antibody biosimilar, Remsima (infliximab), which was rolled out across Europe ...

Early Approvals Pave Smooth Biosimilar Path For Celltrion, Samsung

South Korea's Celltrion and Samsung Bioepis are competing hard to grab a slice of the burgeoning global biosimilar market. Celltrion’s Remicade biosimilar has already been widely launched and may on...

Celltrion Expects Korea Rituximab Approval Despite Biogen Action

Biogen moves to halt Celltrion from selling a rituximab biosimilar in South Korea by seeking a patent scope confirmation trial as the South Korean firm gears up to launch its second biosimilar. But Ce...

Celltrion Adopts Medidata Clinical Cloud

Medidata's ClinicalCloud will provide scalable technology to Celltrion's biosimilars development programs. Date:  Thu, 2016-01-21 (All day) ...

Korea stock? Celltrion stores Remicade biosimilar but minimises risks

Celltrion’s supply chain and warehousing procedures ensure the safe storage of Remicade biosimilars as demand fluctuates across markets, the drugmaker says.

US Panel Favors Celltrion’s Infliximab But Skeptical On Cost Savings

With the favorable backing of a US FDA advisory panel on Feb. 9, which followed a positive review by regulators, Celltrion and its partner, Pfizer unit Hospira, are well on their way to putting the fi...

Real-world biosimilar data driving physician acceptance, says Celltrion

Biosimilar acceptance among physicians has doubled to 80% since 2013, according to a survey presented at by copycat biologic distributor Celltrion Healthcare.

Celltrion: Data support switching to Remicade biosimilar

Celltrion Inc. (KOSDAQ:068270) presented data from 10 real-world switching studies showing that biosimilar infliximab (CT-P13) had "comparable efficacy and safety" to reference product Remicade inflix...

Matching PubMed Articles

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement